Navigation Links
Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Date:1/18/2008

Great Neck, N.Y., Jan. 18 /PRNewswire/ -- On January 17, 2008, the law firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin Simes Kaiser and Gornick LLP, Bailey Perrin Bailey LLP and Weitz & Luxenberg, P.C., have filed over a Billion ($1,000,000,000) Dollar Class Action lawsuit claiming refunds for purchasers of Vytorin, in Federal District Court, Eastern District of New York, Docket #08-258 before The Honorable Carol Bagley Amon, Judge of the United States Eastern District Court of New York, against Merck & Co., Inc. and Schering-Plough Corporation. The class action seeks, in part, refunds to individuals who were prescribed and purchased the popular cholesterol statin drug, Vytorin(R). Vytorin(R) is a single pill combination of two drugs, Zocor and Zetia, (ezetimibe plus simvastatin).

The lawsuit alleges that Merck & Co., Inc. and Schering-Plough Corporation, the manufacturers of the prescription drug, Vytorin(R), made misrepresentations and withheld significant information in its approval submissions and filings with the Federal Drug Administration. It is also alleged that misrepresentations were made to the general public through marketing efforts as to the effectiveness of the drug. In reality, studies have shown that it is no better than other available drugs on the market in lowering cholesterol.

The above law firms have been contacted and retained by many individuals, including the proposed class representative, who have been prescribed and used Vytorin(R) and who are seeking refunds for their prescriptions.

If you or someone you know was prescribed and purchased, Vytorin(R), please contact our office by visiting our website at http://www.yourlawyer.com. Free case evaluations are also available by calling Parker Waichman Alonso LLP at 1-800-LAW-INFO (1-800-529-4636).


'/>"/>
SOURCE Parker Waichman Alonso LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
4. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
10. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
11. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at ... his internship in internal medicine at the Emory University and dermatology training at ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a ... The winner will earn a $1,000 scholarship and have his or her video posted ... the deadline is May 31, with the winner announced on June 9. , The ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
Breaking Medicine News(10 mins):